Safety of an extended-release injectable 10% moxidectin suspension

The safety of an extended-release injectable suspension of 10% moxidectin was evaluated in four studies using Beagle dogs and one study using ivermectin-sensitive Collies at a recommended dose is 0.5 mg/kg subcutaneously once yearly.

RESULTS: 

In study 1: slight swelling was detectable at some of the  3 and 5 times recommended dose.  

Studies 2 and 3 showed no ill effects identified in reproductive (females) or semen quality characteristics (males). 

Study 4: Showed no adverse effects. 

Study 5: there were no abnormal clinical signs at the recommended dose and also at 3 and 5 times the recommended dose in ivermectin-sensitive dogs.    

Read more by clicking on the link below:

Safety of an extended-release injectable moxidectin suspension formulation in dogs.